1. Scrip
  2. >>New Products

IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors

Zeposia Adds A Second Oral Advanced Therapy

 
• By Mandy Jackson

The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.

Pain in human intestines, bowel concept
The IBD market is crowded but with room for improvement • Source: Shutterstock

Inflammatory bowel disease is an increasingly crowded market with an influx of novel therapies recently launched or nearing approvals. The good news for up-and-coming treatments is that established products leave a lot of room for improvement. The bad news is that novel drugs for ulcerative colitis and Crohn’s disease will compete with entrenched therapeutics, such as AbbVie Inc.’s TNF inhibitor Humira (adalimumab) and Johnson & Johnson’s interleukin-12 (IL-12)/IL-23 inhibitor Stelara (ustekinumab), for which biosimilars will be available in the next one to two years.

While anti-TNF biologics and other advanced therapies are the standard of care after conventional front-line therapeutics for ulcerative colitis (UC) and Crohn’s disease (CD) patients, Humira biosimilars could make for formidable challengers – but, as many drug makers are quick to point out, only a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.